Myelodysplastic Syndromes

Our specialists provide expert care for people with myelodysplastic syndromes (MDS). These are conditions in which the blood-forming cells in the bone marrow are damaged, leading to a decreased number of red blood cells, white blood cells, or platelets. We use sophisticated testing to identify the type of MDS and determine the risk of the condition progressing. Then, we create a personalized and evidence-based treatment plan to meet your needs, ranging from watchful monitoring to stem cell transplantation.

Clinical Trials and Research Studies

Phase 3

A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Learn More

Phase 2

AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Learn More

Phase 1

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Learn More